Press Releases

Bolt Biotherapeutics Closes $93.5 Million Series C Financing Read More

Bolt Biotherapeutics Announces Issuance of U.S. Patent for the Boltbody™ ISAC Technology and its Lead Development Candidate, BDC-1001 Read More

Bolt Biotherapeutics Appoints William P. Quinn as Chief Financial Officer Read More

Bolt Biotherapeutics Appoints Edith Perez, M.D., as Chief Medical Officer Read More

Bolt Biotherapeutics Appoints Nathan Ihle, Ph.D., as Vice President of CMC and Quality Read More

Bolt Biotherapeutics Announces Initiation of BDC-1001 Clinical Trial in Patients with HER2-Expressed Solid Tumors Read More

Bolt Biotherapeutics Appoints Dr. Nils Lonberg to its Scientific Advisory Board Read More

Bolt Biotherapeutics Expands Scientific Advisory Board with Appointment of Dr. Priti Hegde Read More

Bolt Biotherapeutics Presents Data At SITC Conference Showing Eradication of Large Tumors in Preclinical Studies Read More

Bolt Strengthens Scientific Advisory Board Through Addition of Drs. Lawrence Fong, Roy Herbst and Bruce Roth Read More

Media Coverage

Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs

Xconomy

Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement

ADC Review

U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in the Development of BDC-1001

ADC Review

Randall Schatzman, Ph.D. to Lead Growth of Immune- Stimulating Antibody Conjugates at Bolt Biotherapeutics

ADC Review

How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy

ADC Review

Bolt Biotherapeutics Nabs $93.5M to Push Provenge Inventor’s New Idea Deeper in the Clinic

Endpoints News

Bolt’s Myeloid Twist on ADCs Charged up with $93.5M series C

BioCentury

Pfizer-Backed Bolt Therapeutics Strikes $93.5M Funding Round As Lead Med Hits the Clinic

Fierce Biotech

Agonist ecstasy? HER2 (and more) ‘Bolt’-on strategy draws $93.5M series C

BioWorld

Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors

Precision Oncology News

Podcasts

Dr. Randy Schatzman On Dodging Disruption: The New Fundraising Norm

Business of Biotech Podcast

Listen Now

CMC Considerations For In-Human Studies with Drs. Edith Perez And Nathan Ihle

Business of Biotech Podcast

Listen Now

Randy Schatzman, PhD, CEO of Bolt Biotherapeutics

Biotech 2050 Podcast

Listen Now

Advances in Targeted Cancer Therapy
with Dr. Edith Perez

Empowered Patient Podcast

Listen Now

Posters & Publications

HER2-targeting TLR 7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR-dependent manner

Presented at: 2019 Society for Immunotherapy of Cancer (SITC)

TLR7/8 immune stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity

Presented at: 2019 American Association for Cancer Research (AACR)

Systemic Immunity is Required for Effective Cancer Immunotherapy

Spitzer MH, et al. Cell (2017)

Allogenic IgG Combined with Dendritic Cell Stimuli Induce Antitumor T-cell Immunity

Carmi Y, et al. Nature (2015)